Comments
Piramal Enterprises today said it has completed acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC.
Piramal in January had announced the acquisition for a cash consideration of $171 million and up to an additional $32 million payable depending on financial performance of the acquired assets over the next three years.
“Piramal Enterprises announced that its wholly-owned Critical Care subsidiary in the UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC,” the company said in a BSE filing.
Piramal’s critical care business is a global player in the hospital generics segment. It is the world’s third largest producer of inhaled anaesthetics.
The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the US and two pain management products, which are under development at present, the filing said.
In the twelve months ended September 30, 2016, the acquired portfolio generated revenues of $44.6 million.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.